Ontology highlight
ABSTRACT:
SUBMITTER: Scheffold A
PROVIDER: S-EPMC8212352 | biostudies-literature | 2019 Aug
REPOSITORIES: biostudies-literature
Scheffold Annika A Jebaraj Billy Michael Chelliah BMC Tausch Eugen E Bloehdorn Johannes J Ghia Paolo P Yahiaoui Anella A Dolnik Anna A Blätte Tamara Jacqueline TJ Bullinger Lars L Dheenadayalan Rashmi Priyadharshini RP Li Li L Schneider Christof C Chen Shih-Shih SS Chiorazzi Nicholas N Dietrich Sascha S Seiffert Martina M Tannheimer Stacey S Döhner Hartmut H Mertens Daniel D Stilgenbauer Stephan S
Blood 20190422 6
Targeted therapy is revolutionizing the treatment of cancers, but resistance evolves against these therapies and derogates their success. The phosphatidylinositol 3-kinase delta (PI3K-δ) inhibitor idelalisib has been approved for treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma, but the mechanisms conferring resistance in a subset of patients are unknown. Here, we modeled resistance to PI3K-δ inhibitor in vivo using a serial tumor transfer and treatment scheme in mice. Wh ...[more]